Tybourne Capital Management (hk) Ltd.

In its 13F for Q3 2025 (holdings as of September 30, 2025, filed November 6, 2025), Tybourne Capital Management (hk) Ltd. reported 4 stock positions worth $30.9 million. Its top holding was Taysha Gene Therapies (TSHA) at 39.1% of the portfolio, followed by Forte Biosciences (FBRX, 38.1%) and Alumis (ALMS, 18.0%). Compared with Q2 2025, it sold out of 2 and reduced 2. The biggest sale was an exit from Bicycle Therapeutics PLC-ADR (BCYC).

Most Recent 13F
Q3 2025
Location
HONG KONG, K3
CIK
0001553936
Portfolio Value
$30.9M (Q3 2025)
SEC Filing
0001553936-25-000013 ↗ filed Nov 6, 2025

Holdings Value

0$200.0M$400.0M$600.0M Q1 2024: $584.9M Q1 2024 Q2 2024: $491.7M Q2 2024 Q3 2024: $356.7M Q3 2024 Q4 2024: $398.4M Q4 2024 Q1 2025: $23.6M Q1 2025 Q2 2025: $34.5M Q2 2025 Q3 2025: $30.9M $30.9M Q3 2025

Holdings 4 stocks · $30.9M
TSHA Taysha Gene Therapies Inc. 39.11% 3,700,000 $12.1M Reduce -9.7%
FBRX Forte Biosciences Inc. 38.15% 786,647 $11.8M No change
ALMS Alumis Inc. 18.05% 1,399,250 $5.6M No change
ZNTL Zentalis Pharmaceuticals Inc. 4.69% 961,486 $1.5M Reduce -35.0%

Portfolio Sells Q2 2025 → Q3 2025
BCYC Bicycle Therapeutics PLC-ADR Sold out 0.00% −20.00
MBUU Malibu Boats Inc. Class A Sold out 0.00% −6.05
ZNTL Zentalis Pharmaceuticals Inc. Reduce -35.0% 4.69% −0.27
TSHA Taysha Gene Therapies Inc. Reduce -9.7% 39.11% +11.73

Portfolio Buys Q2 2025 → Q3 2025
None this quarter.

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q3 2025 4$30.9MTSHA, FBRX, ALMS, ZNTL
Q2 2025 6$34.5MFBRX, TSHA, BCYC, ALMS, MBUU
Q1 2025 5$23.6MSLRN, TSHA, BCYC, FBRX, ZNTL
Q4 2024 33$398.4MCP, IQV, ADSK, EPAM, LPLA
Q3 2024 32$356.7MTXN, CP, LPLA, EPAM, IQV
Q2 2024 36$491.7MTXN, CP, ZG, EPAM, IQV
Q1 2024 38$584.9MCP, TXN, IQV, LIN, BCYC